Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 10, 2017 in Lung cancer | 0 comments

In a nutshell

This study examined the use of a type of targeted therapy called immune checkpoint inhibitors to treat advanced non-small-cell lung cancer (NSCLC). The authors concluded that for patients who had a genetic mutation (change) called KRAS, ICIs were more effective than chemotherapy. They suggest that the presence of KRAS mutations could predict the type of treatment a patient gets.

Some background

Treatment of non-small-cell lung cancer (NSCLC) is now focused more on targeted therapy where treatment is specific for the individual patient. One new type of treatment are immune checkpoint inhibitors (ICIs). ICIs act by blocking a protein present on tumor cells which then activates the immune system to fight the tumor.

Methods of predicting which treatments may be effective would be beneficial. One possible marker is the presence of a KRAS mutation (change), which is common in NSCLC. Studies thus far show conflicting results on whether this would be a good marker or not.

Methods & findings

This meta-analysis aimed to determine whether the presence of a KRAS mutation affects the outcome of ICIs in patients with advanced NSCLC. Three trials were included with a combined 509 patients. Of these, 138 patients had KRAS mutations and 371 did not.

For patients who had KRAS mutations, ICIs resulted in 36% improved overall survival (OS, time from beginning trial until death) compared to chemotherapy. For patients who did not have KRAS mutations, ICIs did not improve OS compared to chemotherapy.

The bottom line

The authors concluded that for patients with KRAS mutation positive NSCLC, ICIs are an effective treatment. They suggested that the presence of KRAS mutations could be a biomarker to determine whether to use ICIs or not.

Published By :


Date :

May 05, 2017

Original Title :

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A metaanalysis and review.

click here to get personalized updates